RxDoctor Payments Data

Ravinder Sabherwal

Optometrist · Erie, PANPI 1609840024

Payments from drug & device makers

$4,388in general payments, 2019–2025

Across 124 payments — averaging $35.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$535
  • Bausch & Lomb Americas Inc.$472
  • AbbVie$450
  • Aerie Pharmaceuticals, Inc.$248
  • Sun Pharmaceutical Industries Inc.$136
  • plus $646 from 15 others

What the payments were for

  • Speaking & faculty fees$1,12526%
  • Food & beverage$3,26374%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,388 in reported general payments places this provider in the 90th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$107,678
Medicare patients
709
Services billed
970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost126$58,364
RestasisCyclosporine14$11,369
Alphagan PBrimonidine Tartrate33$9,539
CombiganBrimonidine Tartrate/Timolol25$8,433
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$5,682
Timolol Maleate110$5,288
Brimonidine Tartrate33$4,392
Latanoprost462$4,084
RocklatanNetarsudil Mesylat/Latanoprost11$3,654
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat123$1,698
Loteprednol Etabonate13$1,252
TafluprostTafluprost/Pf12$953
Prednisolone Acetate17$749
ValacyclovirValacyclovir Hcl18$584
Tobramycin-DexamethasoneTobramycin/Dexamethasone17$565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$450$87,705198 claims
Aerie Pharmaceuticals, Inc.Rocklatan$248$3,65411 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$535$1,25213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →